Glucagon-like peptide 1 receptor (GLP-1R) agonism is a validated approach for treating obesity. ECC-4703 is a small molecule and liver-targeting compound developed by Eccogene Co. Ltd. It is an ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Panelists highlight that oral endocrine therapies for hormone receptor-positive breast cancer are generally well tolerated ...

Researchers in France have developed an antibody that blocks AMH, reversing PCOS symptoms in mice and opening the door to future human trials.

ASC-47 is a thyroid hormone receptor β agonist, muscle-preserving weight loss compound for treating obesity developed by Ascletis Pharma Inc. ASC-47 demonstrated a half-life of 26 and 40 days in ...

This year's American Society of Clinical Oncology (ASCO) meeting delivered a packed agenda of breast cancer research, with major updates for antibody-drug conjugates, HER2-positive regimens, and ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Tesamorelin, a synthetic growth hormone-releasing hormone (GHRH) analog, has garnered significant attention in scientific ...

A team from the Institut Curie, Inserm, and CNRS[1] has uncovered a new molecular mechanism, previously unknown, linking ...

Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...

Imagine a drug that halts cancer without side effects or risks. That future may be a bit nearer thanks to recent research led ...